CoChat

Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence

van Genugten, R. E., van Raalte, D. H., Diamant, M. · 2012 · Diabetes, Obesity and Metabolism
Cited by 73

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus (T2DM) develops as a consequence of progressive β ‐cell dysfunction in the presence of insulin resistance. None of the currently‐available T2DM therapies is able to change the course of the disease by halting the relentless decline in pancreatic islet cell function. Recently, dipeptidyl peptidase (DPP)‐4 inhibitors, or incretin enhancers, have been introduced in the treatment of T2DM. This class of glucose‐lowering agents enhances endogenous glucagon‐like peptide 1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) levels by blocking the incretin‐degrading enzyme DPP‐4. DPP‐4 inhibitors may restore the deranged islet‐cell balance in T2DM, by stimulating meal‐related insulin secretion and by decreasing postprandial glucagon levels. Moreover, in rodent studies, DPP‐4 inhibitors demonstrated beneficial effects on (functional) β ‐cell mass and pancreatic insulin content. Studies in humans with T2DM have indicated improvement of islet‐cell function, both in the fasted state and under postprandial conditions and these beneficial effects were sustained in studies with a duration up to 2 years. However, there is at present no evidence in humans to suggest that DPP‐4 inhibitors have durable effects on β ‐cell function after cessation of therapy. Long‐term, large‐sized trials using an active blood glucose lowering comparator followed by a sufficiently long washout period after discontinuation of the study drug are needed to assess whether DPP‐4 inhibitors may durably preserve pancreatic islet‐cell function in patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01473.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 73

Metadata

Authors
van Genugten, R. E., van Raalte, D. H., & Diamant, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-11-21
Volume
14
Issue
2
Pages
101-111
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2072114549
Cited by
73
References
26
FWCI
6.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01473.x
The paper
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012). Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01473.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.